Patents by Inventor Penelope Andreux

Penelope Andreux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260132117
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: October 21, 2025
    Publication date: May 14, 2026
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Duncan Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Patent number: 12576065
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Grant
    Filed: April 4, 2025
    Date of Patent: March 17, 2026
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 12544358
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: February 10, 2026
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Publication number: 20250381118
    Abstract: The invention provides a compound of formula (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; or a salt thereof; for use in the treatment and/or prevention of a skin condition in a subject, wherein the compound of formula (I) or salt thereof is administered topically. The invention further provides topical compositions of a compound of formula (i) and processes for the preparation of said compositions.
    Type: Application
    Filed: February 13, 2025
    Publication date: December 18, 2025
    Inventors: Christopher L. Rinsch, Penelope Andreux, Anurag Singh
  • Publication number: 20250375415
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Application
    Filed: August 27, 2025
    Publication date: December 11, 2025
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 12473269
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: November 18, 2025
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Publication number: 20250228816
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Application
    Filed: April 4, 2025
    Publication date: July 17, 2025
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Publication number: 20250228817
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Application
    Filed: April 4, 2025
    Publication date: July 17, 2025
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 12358884
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: July 15, 2025
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Patent number: 12351567
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: July 8, 2025
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Patent number: 12310943
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: May 27, 2025
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Patent number: 12297182
    Abstract: The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.
    Type: Grant
    Filed: January 19, 2024
    Date of Patent: May 13, 2025
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher L. Rinsch, William Blanco-Bose
  • Patent number: 12220424
    Abstract: A composition comprising: a) nicotinamide riboside and b) a urolithin which is a compound of formula (I) or a salt thereof: wherein: A, B, C and D are each independently selected from H and OH; W, X and Y are each independently selected from H and OH; and Z is selected from H and OH. The compositions are useful as medicaments, for example for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases and as dietary supplements, functional foods and beverages, and specialised nutrition or medical foods.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: February 11, 2025
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher L. Rinsch
  • Publication number: 20240424006
    Abstract: Disclosed are methods of treating amyotrophic lateral sclerosis (ALS). Also disclosed are methods of treating C9orf72 amyotrophic lateral sclerosis (C9-ALS).
    Type: Application
    Filed: May 17, 2024
    Publication date: December 26, 2024
    Inventors: Penelope Andreux, Klaus Andreas Dugi
  • Patent number: 12109190
    Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 8, 2024
    Assignee: Amazentis SA
    Inventors: Anurag Singh, Davide D'Amico, Penelope Andreux, William Blanco-Bose, Christopher L. Rinsch
  • Patent number: 12036205
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: July 16, 2024
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Publication number: 20240158364
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhen, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Publication number: 20240158365
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Publication number: 20240158363
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Publication number: 20240156777
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux